Identification of 13q deletion, trisomy 1q, and IgH rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma

Cancer Genetics and Cytogenetics

Volumn 168, Issue 2, 2006, Pages 124-132

  Bang, Soo Mee ^a   Kim, Young Ree ^b   Cho, Han Ik ^c   Chi, Hyun Sook ^d   Seo, Eul Ju ^d   Park, Chan Jeoung ^d   Yoo, Soo Jin ^d   Kim, Hee Chan ^c   Chun, Hong Gu ^c   Min, Hyun Chung ^c   Oh, Bo Ra ^c   Kim, Tae Young ^c   Lee, Jae Hoon ^a   Lee, Dong Soon ^c  

^a Gachon University College of Medicine   (South Korea)

^b Jeju National University School of Medicine   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN P16; PROTEIN P53;

ADULT; AGED; ANEMIA; ARTICLE; CANCER STAGING; CAUCASIAN; CHROMOSOME 13Q; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE DELETION; GENE TRANSLOCATION; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; HUMAN; HUMAN CELL; KOREA; MAJOR CLINICAL STUDY; MALE; MOLECULAR PROBE; MULTIPLE MYELOMA; PLASMACYTOSIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN BLOOD LEVEL; THROMBOCYTOPENIA; TRISOMY; TRISOMY 11; TRISOMY 1Q; UREMIA;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 13; FEMALE; GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN; HUMANS; IMMUNOGLOBULINS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERPHASE; KARYOTYPING; KOREA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLOIDIES; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TRISOMY; TUMOR CELLS, CULTURED;

EID: 33745855515     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2006.02.015     Document Type: Article

References (28)

1. Ries L.A.G., Eisner M.P., and Kosary C.L. SEER Cancer statistics review, 1975-2002 (2004), National Cancer Institute, Bethesda
2. Korea Central Cancer Registry. 2002 Annual report of the Korea Central Cancer Registry (based on registered data from 139 hospitals) (2004), Ministry of Health and Welfare, Seoul
3. The Research Group for Population-based Cancer Registration in Japan. Cancer incidence and incidence rates in Japan in 1999: estimates based on data from 11 population-based cancer registries. Jpn J Clin Oncol 34 (2004) 352-356
4. Togawa A., Amano M., and Takaku F. The epidemiology of multiple myeloma in Japan. Japan Med J 3462 (1990) 31-34
5. Central and Regional Cancer Registry Center. Cancer incidence in Korea: 1999-2001 (2005), Ministry of Health and Welfare, Seoul
6. Perez-Simon J.A., Garcia-Sanz R., Tabernero M.D., Almeida J., Gonzalez M., Fernandez-Calvo J., Moro M.J., Hernandez J.M., San Miguel J.F., and Orfao A. Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. Blood 91 (1998) 3366-3371
7. Zojer N., Konigsberg R., Ackermann J., Fritz E., Dallinger S., Kromer E., Kaufmann H., Riedel L., Gisslinger H., Schreiber S., Heinz R., Ludwig H., Huber H., and Drach J. In multiple myeloma, deletion of 13q14 remains an independent adverse prognostic parameter despite its frequent detection by interphase FISH. Blood 95 (2000) 1925-1930
8. 2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97 (2001) 1566-1571
9. Fonseca R., Harrington D., Oken M.M., Dewald G.W., Bailey R.J., Van Wier S.A., Henderson K.J., Blood F.A., Rajkumar S.V., Kay N.F., Van Ness B., and Greipp P.R. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (Δ3) in multiple myeloma: an Eastern Cooperative Oncology Group study. Cancer Res 62 (2002) 715-720
10. Fonseca R., Barlogie B., Bataille R., Bastard C., Bergsagel P.L., Chesi M., Davies F.E., Drach J., Greipp P.R., Kirsch I.R., Kuehl W.M., Hernandez J.M., Minvielle S., Pilarski L.M., Shaughnessy Jr. J.D., Stewart A.K., and Avet-Loiseau H. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64 (2004) 1546-1558
11. Avet-Loiseau H., Facon T., Grosbois B., Magrangeas F., Rapp M.J., Harousseau J.L., Minvielle S., and Bataille R. (Intergroupe Francophone du Myelome). Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 99 (2002) 2185-2191
12. Fonseca R., Blood E., Rue M., Harrington D., Oken M.M., Kyle R.A., Dewald G.W., Van Ness B., Van Wier S.A., Henderson K.J., Bailey R.J., and Greipp P.R. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101 (2003) 4569-4575
13. Athanasiou E., Kaloutsi V., Kotoula V., Hytiroglou P., Kostopoulos I., Zervas C., Kalogiannidis P., Fassas A., Christakis J.I., and Papadimitriou C.S. Cyclin D1 overexpression in multiple myeloma a morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens. Am J Clin Pathol 116 (2001) 535-542
14. Tricot G., Barlogie B., Jagannath S., Bracy D., Mattox S., Vesole D.H., Naucke S., and Sawyer J.R. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86 (1995) 4250-4256
15. Smadja N.V., Bastard C., Brigaudeau C., Leroux D., and Fruchart C. Groupe Francais de Cytogenetique Hematologique. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98 (2001) 2229-2238
16. Dewald G.W., Kyle R.A., Hicks G.A., and Greipp P.R. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 66 (1985) 380-390
17. Sawyer J.R., Waldron J.A., Jagannath S., and Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 82 (1995) 41-49
18. Drach J., Schuster J., Nowotny H., Angerler J., Rosenthal F., Fiegl M., Rothermundt C., Gsur A., Jager U., and Heinz R. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res 55 (1995) 3854-3859
19. Flactif M., Zandecki M., Lai J.L., Nernardi F., Obein V., Bauters F., and Facon T. Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma. Leukemia 9 (1995) 2109-2114
20. Tabernero D., San Miguel J.F., Garcia-Sanz R., najera L., Garcia-Isidoro M., Perez-Simon J.A., Gonzalez M., Wiegant J., Raap A.K., and Orfao A. Incidence of numerical chromosome changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes. Am J Pathol 149 (1996) 153-161
21. Durie B.G.M. Staging and kinetics of multiple myeloma. Semin Oncol 13 (1986) 300-309
22. Pedersen B., and Kerndrup G. Specific minor chromosome deletions consistently occurring in myelodysplastic syndromes. Cancer Genet Cytogenet 23 (1986) 61-75
23. ISCN. International system for human cytogenetic nomenclature. In: Mittelman F. (Ed) (1995), S. Karger, Basel
24. Hallek M., Bergsagel P.L., and Anderson K.C. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91 (1998) 3-21
25. Shaughnessy J., Jacobson J., Sawyer J., McCoy J., Fassas A., Zhan F., Bumm K., Epstein J., Anaissie E., Jagannath S., Vesole D., Siegel D., Desikan R., Munshi N., Badros A., Tian E., Zangari M., Tricot G., Crowley J., and Barlogie B. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood 101 (2003) 3849-3856
26. Elnenaei M.O., Hamoudi R.A., Swansbury J., Gruszka-Westwood A.M., Brito-Babapulle V., Matutes E., and Catovsky D. Delineation of the minimal region of loss at 13q14 in multiple myeloma. Genes Chromosomes Cancer 36 (2003) 99-106
27. Sakai C., Matsubayashi K., Saotome T., Ishii A., and Kumagai K. Therapy-related myelodysplastic syndrome with trisomy 1q due to der(1;7) and megakaryoblastic proliferation developing during complete remission of therapy-related acute myeloid leukemia with t(8;21). Int Med 43 (2004) 582-586
28. Bersagel P.L., Kuehl W.M., Zahn F., Sawyer J., Barlogie B., and Shaughnessy J. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106 (2005) 296-303